Month: May 2024

iCAD Reports Financial Results for First Quarter Ended March 31, 2024

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance):Total ARR was $9.0 million, up 10% Total revenues were $5.0 million, up 14% Gross Profit Margin % was 83%, up from 82% GAAP Net Loss from continuing operations ($1.2) million, improvement from ($3.1) million Operating cash flow was ($1.2) million, improvement from ($1.5) million“Over the past year, we have demonstrated strong execution of our three-phased transformation plan that has positioned iCAD for growth and created a platform to drive additional shareholder value,”...

Else Nutrition Reports 2024 First Quarter Financial Results and Provides Business Update

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Continuing to add major retail partners; now serving thousands of stores across North America Amazon sales increased approximately 92% and 330% over the same quarter last year in the U.S. and Canada, respectively Conference Call to be Held Today at 10:00 AM Eastern TimeImage: Notable retailers added by Else Nutrition during the first quarter of 2024 VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”), today reported financial results for the first quarter ended March 31, 2024. The financial statements and MD&A are available on SEDAR under the Company’s profile. “We are proud of our strong start to 2024 with multiple, significant retail partners signing on to carry our products,” commented, Hamutal Yitzhak, CEO...

Blüm Holdings Inc. Reports First Quarter 2024 Financial Results

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

SANTA ANA, Calif., May 15, 2024 (GLOBE NEWSWIRE) — Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “we” or “us”), a cannabis company which through its subsidiaries has operations throughout California, announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 HighlightsThe Company continued to eliminate non-performing legacy operations during the first quarter of 2024 and transitioned a single retail location to delivery only. As a result, revenue for the first quarter of 2024 was $6.8 million, down from $8.1 million in the previous quarter ended December 31, 2023.For five consecutive quarters in a row, the Company has maintained a gross margin of above 50%, landing at 53% for the first quarter of 2024.Operating expenses for the first quarter of 2024 were $6.1 million, a decrease...

CAPREIT Announces May 2024 Distribution

Written by Customer Service on May 15, 2024. Posted in Dividend Reports And Estimates.

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) — Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) announced today its May 2024 monthly distribution in the amount of $0.12083 per Unit (or $1.45 on an annualized basis). The May 2024 distribution will be payable on June 17, 2024 to Unitholders of record at the close of business on May 31, 2024. CAPREIT is Canada’s largest publicly traded provider of quality rental housing. As at March 31, 2024, CAPREIT owns approximately 64,200 residential apartment suites, townhomes and manufactured home community sites well-located across Canada and the Netherlands, with approximately $16.7 billion of investment properties in Canada and Europe. Since its Initial Public Offering in May 1997, CAPREIT has grown monthly cash distributions per Unit by 103%. For more information...

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

Written by Customer Service on May 15, 2024. Posted in Public Companies.

MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator for the Company’s Phase 2b clinical trial of enobosarm to preserve muscle while augmenting fat loss in patients receiving a GLP-1 RA for weight loss. Dr. Heymsfield is a leading authority on body composition assessment and his research focuses primarily on human obesity, including energy balance regulation, weight loss treatments, co-morbidity...

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

Written by Customer Service on May 15, 2024. Posted in Public Companies.

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person Phase 2 clinical trial investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). Participants were randomized to placebo, 1 mg, and 2 mg daily doses of (Z)-endoxifen and treated for six months, over the course of which mammograms are conducted to measure reduction in MBD. Medication-induced MBD...

Progressive Reports April 2024 Results

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

MAYFIELD VILLAGE, OHIO, May 15, 2024 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended April 30, 2024: April(millions, except per share amounts and ratios; unaudited) 2024Net premiums written $ 6,178.0 Net premiums earned $ 5,575.0 Net income $ 420.3 Per share available to common shareholders $ 0.72 Total pretax net realized gains (losses) on securities $ (266.1 )Combined ratio – current year 89.0 – prior year month 97.9 Average diluted equivalent common shares 587.4 In October 2023, we converted our monthly accounting closing calendar to align with the Gregorian calendar. We do not expect that this change will have a material impact on our reported quarterly and annual underwriting results but it may impact...

Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D., to Chief Scientific Officer, Dennis Dean, Ph.D., to Chief Non-Clinical Development Officer, and the promotion of Jennifer Dittman to Chief Development Operations Officer Strong financial position with cash and cash equivalents totaling $262.8 million as of March 31, 2024 SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) — Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced financial results for the first quarter March 31,...

Nayax Reports First Quarter 2024 Financial Results

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Strong first quarter with recurring revenue up 43% YoY; Total revenue of $64 million; Adjusted EBITDA of $3.6 million (1); Improving profitability with gross margins reaching 43.8% Reiterates full year 2024 guidance: revenue between $325-335 million, representing 38% YoY growth and adjusted EBITDA between $30–35 million, over 266% YoY growth (2) HERZLIYA, Israel, May 15, 2024 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX, TASE: NYAX), a global commerce payments and loyalty platform designed to help merchants scale their business, today announced its financial results for the first quarter, ended March 31, 2024. “I am pleased with our first quarter results, which continued our strong trajectory, and especially with the significant improvements in recurring revenue, gross margins, and adjusted EBITDA. As we look ahead through...

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024 and recent corporate progress. “We are grateful to our existing as well as new investors who have demonstrated their support through the recent financing, which has extended our cash runway into 2026, well beyond anticipated regulatory milestones,” said Vish Seshadri, Chief Executive Officer of Abeona. “We now remain focused on working with the FDA to address the CMC deficiencies noted in the CRL and making the BLA resubmission to bring pz-cel to RDEB patients as soon as possible.” First Quarter and Recent Progress Corporate highlightsOn May 7,...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals